An undisputed fact is that clinical trial delays are very costly. Any strategies that accelerate start-up are key to a study’s success in achieving timelines and expected budget. However, these drivers should not challenge the ultimate key objective of obtaining high-quality data without over-burdening the sites or the participants. In this webinar, the featured speakers will provide insights on how to address common challenges in neuroimaging studies.
This webinar includes:
- An overview of key considerations that impact start-up cycle times in neuroimaging clinical studies with strategies and tactics to address them
- How to adopt a centralised approach to reduce cycle times in qualifying sites anywhere in the world
- How to reduce the burden to sites and patients
In addition to clinical operations experts, attendees will hear a site’s perspective about the key requirements to obtain high-quality data efficiently and quickly.
Register today to learn more about getting neuroimaging right and succeeding in neurodegenerative clinical trials.
Vicky Eyre, Director, Clinical Operations, Re:Cognition Health
Vicky Eyre has worked in the clinical trials industry for over 15 years, in both academic and commercial settings. Vicky has held roles covering clinical trials start-up, delivery and operations, project management and quality assurance, covering Phase I to IV, across multiple therapeutic areas. In Vicky’s current Clinical Operations Director role, she supports the business development, clinical trial start-up and delivery of commercial neurology trials, primarily in Alzheimer’s, overseeing the six UK Re:Cognition Health Ltd clinic teams. Vicky is passionate about developing her high-performing teams, promoting rapid start-up, patient participation in research and supporting the development of the UK research industry. A key component of the success of Re:Cognition health is the passion for research and identifying and collaborating with high quality clinical trial vendors who share the same motivations, enabling streamline set up and high-quality data delivery.
Romina Oxborough, PhD, Senior Vice-President Operations, IXICO
Romina Oxborough has over 20 years of experience in the life sciences and pharmaceutical sector. Prior to IXICO, Romina held senior leadership roles focused on supporting clinical trials and patients’ access to medicines (Avenir Global, Clinigen, IQVIA). Romina has a track record of building profitable business units underpinned by excellent operational delivery. Her role at IXICO is accountable for best-in-class delivery of neuroimaging clinical trials for global pharmaceutical companies. A PhD and MBA-trained innovative leader with a passion for developing high-performing teams, Romina leads the Operations team at IXICO. Romina is a Diversity and Inclusion Board member and mentor for a non-for-profit organisation (HBA).
Nicoletta Vitale, Senior Project Start-Up Manager, IXICO
Nicoletta Vitale has over eight years of experience in clinical research, with a focus on streamlined processes to ensure rapid site start-up timelines in imaging-based clinical trials. She holds a master’s degree in medical engineering and physics from King’s College London and, in her current role, leads the project start-up team at IXICO. Successful imaging site set-up is a critical step for obtaining standardised imaging acquisition and high-quality data, and her team achieves this through robust technical evaluation, comprehensive site training and set-up of scanners for global imaging centres.
Who Should Attend?
- Operations Leads
- Business Development Professionals
- Imaging & Biomarker Specialists from pharmaceutical & biotechnology companies
- Project Managers & BD Professionals from CROs
- Clinical & Imaging Sites
What You Will Learn
Attendees will be equipped with best practices for successful imaging, clinical study planning and management.
IXICO is a medical data company, providing data management and advanced analytics to the clinical trials market. Established in 2004, IXICO has firmly established itself as a trusted partner to the global pharmaceutical industry developing new therapies for neurological conditions such as Alzheimer’s, Parkinson’s and Huntington’s diseases.
Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and our goal is to be a leading proponent of artificial intelligence in medical image analysis. We will achieve this by developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the pharmaceutical industry.
Our integrated technology offering encompasses every stage of clinical drug development through to post market assessment and we continue to invest in infrastructure and innovation to support our ambitious growth strategy. We are dedicated to addressing complex unmet needs in clinical development by partnering and collaborating with clients and academic experts early in the drug development cycle to identify and validate promising new imaging and digital biomarkers and to support the clinical development of new drug assets all the way through to commercialisation.